What patent covers Winlevi (clascoterone), and what is it protecting?
Winlevi is the brand name for clascoterone, a topical androgen receptor (AR) inhibitor used for acne. Patents covering Winlevi generally protect the drug substance (clascoterone), key formulations/dosing for topical use, and related methods of treatment. Specific patent numbers and expiration dates depend on the jurisdiction and the particular patent family being asserted.
For a structured view of Winlevi-related patent filings and timelines, see DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/Winlevi/ [1].
When does the Winlevi patent expire (and can exclusivity extend beyond the patent)?
Patent expiry dates depend on the individual patent (not just the product), and exclusivity can extend coverage through regulatory exclusivities in addition to the patent term. The practical “when could generics/biosimilars appear?” question usually turns on:
- the latest expiring patent in the relevant family, and
- any regulatory exclusivity that delays approval of competing products.
DrugPatentWatch compiles these kinds of details for Winlevi and is the quickest way to match a specific patent record to an estimated end date. [1]
Is there a generic or “alternative” to Winlevi that could enter before the patent ends?
If a competitor product is a true generic vs. a different branded topical, timing still depends on what the competitor must prove to the FDA (or other regulators) and whether it can avoid infringing active-ingredient and formulation patents. Many “look-alike” products still get blocked by formulation or method-of-use patents even if they’re not protected by the original drug-substance patent.
To check what companies are listed against Winlevi patent records and which patents drive exclusivity, use the Winlevi page on DrugPatentWatch. [1]
Are companies challenging Winlevi patents in court?
Competitors sometimes challenge listed patents via patent litigation or related legal challenges tied to FDA approval pathways. Whether that happens for Winlevi depends on specific filings in the relevant patent families and jurisdictions.
DrugPatentWatch is a useful starting point for identifying which patents are tied to product exclusivity and who is associated with those records. [1]
Why do some people say the “Winlevi patent” instead of “Winlevi patents”?
Because product protection is usually spread across multiple patents (drug substance, formulation, manufacturing, and clinical/method claims). When people cite “the Winlevi patent,” they often mean:
- the last major blocking patent in the relevant family, or
- the patent most commonly asserted in disputes.
That’s why it’s important to look up the specific patent entry rather than relying on a single date.
---
Sources
[1] https://www.drugpatentwatch.com/patent/Winlevi/